AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced it has received approximately 581,000 Euros for its 2017 CIR (French Research Tax Credit) following the successful conclusion of its audit.
April 1, 2020
· 3 min read